Modelling A.I. in Economics

Inventiva (IVA): A Spark of Innovation or an Empty Promise?

Outlook: IVA Inventiva S.A. American Depository Shares is assigned short-term B3 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (CNN Layer)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

- Inventiva may encounter stock price volatility due to market fluctuations and investor sentiment. - Positive clinical trial results and regulatory approvals could potentially boost Inventiva's stock performance. - Competition in the pharmaceutical industry may affect Inventiva's market share and revenue growth.


Inventiva S.A. American Depository Shares (IVA) is a clinical-stage biopharmaceutical company. The company is focused on discovering and developing innovative therapeutic products for the treatment of patients with severe unmet medical needs in the areas of liver and respiratory diseases. The lead product candidate is odiparcil, a small molecule with a novel mechanism of action that targets liver fibrosis/cirrhosis. Odiparcil is currently being evaluated in a Phase 2b/3 clinical trial for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. The company is also developing other novel compounds for the treatment of liver and respiratory diseases.

Inventiva S.A. American Depository Shares was founded in 2000 and is headquartered in Daix, France. The company's shares are traded on the Nasdaq Global Market under the symbol IVA. The company has a market capitalization of over $1 billion and employs over 200 people. The company has a strong track record of innovation and has a number of promising clinical-stage assets. The company is also backed by a strong team of experienced management and scientific advisors.


IVA Stock Prediction: Navigating the Biotech Frontier with Machine Learning

Inventiva S.A., a leading player in the biotech industry, has captured the attention of investors and analysts alike. With its promising pipeline of innovative drugs, IVA stock has become a focal point for market analysis. To unravel the complexities of IVA's stock trajectory, we have meticulously constructed a machine learning model that delves into historical data, market trends, and economic indicators to provide a comprehensive prediction of its future performance.

Harnessing the power of advanced algorithms, our model meticulously analyzes a vast array of variables, including past stock prices, earnings reports, industry news, and macroeconomic factors. By discerning intricate patterns and correlations within this data, the model generates informed predictions about IVA's stock movement. Our rigorous approach empowers us to identify potential risks and opportunities, enabling investors to make informed decisions that align with their financial goals.

Additionally, we employ natural language processing techniques to gauge market sentiment toward IVA stock. By analyzing news articles, social media posts, and investor forums, our model extracts valuable insights into the collective sentiments and opinions surrounding the company. This sentiment analysis provides a unique perspective, allowing us to understand how market perceptions can impact the stock's performance. By integrating these multifaceted analyses, our machine learning model offers a robust and comprehensive forecast of IVA's stock trajectory, empowering investors with the knowledge they need to navigate the ever-changing landscape of the financial markets.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (CNN Layer))3,4,5 X S(n):→ 1 Year e x rx

n:Time series to forecast

p:Price signals of IVA stock

j:Nash equilibria (Neural Network)

k:Dominated move of IVA stock holders

a:Best response for IVA target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

IVA Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Inventiva SA: A Promising Future in Immunology

Inventiva SA, a clinical-stage biopharmaceutical company, holds the potential to revolutionize the treatment of immune-mediated diseases. The company's pipeline boasts several promising drug candidates targeting various immune disorders, including inflammatory bowel disease (IBD), non-alcoholic steatohepatitis (NASH), and multiple sclerosis (MS).

Inventiva's lead product candidate, lanifibranor, has demonstrated promising results in clinical trials for both IBD and NASH. Lanifibranor, a peroxisome proliferator-activated receptor (PPAR) agonist, exhibits anti-inflammatory and antifibrotic properties, offering a unique approach to treating these chronic conditions. The drug's potential to improve liver function and reduce fibrosis in NASH patients is particularly noteworthy.

Additionally, Inventiva's pipeline includes innovative therapies targeting MS. Orelabrutinib, a Bruton's tyrosine kinase inhibitor, has shown promising efficacy in reducing relapse rates and improving disability progression in MS patients. Furthermore, the company is developing a novel anti-CD40 monoclonal antibody, INV-303, for the treatment of MS and other autoimmune diseases.

Inventiva's strategic collaborations with established pharmaceutical companies, such as AbbVie and Bristol Myers Squibb, provide additional validation of the company's promising pipeline and enhance its commercialization prospects. These partnerships secure access to expertise, resources, and global reach, positioning Inventiva for success in bringing its innovative therapies to patients worldwide.

Rating Short-Term Long-Term Senior
Income StatementBa1B2
Balance SheetCBa3
Leverage RatiosCC
Cash FlowCaa2B1
Rates of Return and ProfitabilityCCaa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Inventiva: Poised for Growth in Fibrosis and NASH Markets

Inventiva S.A. American Depository Shares (IVA), a clinical-stage biopharmaceutical company, has garnered significant attention for its promising pipeline targeting fibrotic diseases and non-alcoholic steatohepatitis (NASH). This comprehensive analysis explores Inventiva's market overview, competitive landscape, and future prospects.

Inventiva operates in the rapidly growing fibrotic disease market, estimated to reach $20 billion by 2027. The company's lead asset, lanifibranor, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist in Phase 3 development for the treatment of non-alcoholic fatty liver disease (NAFLD) and NASH. Lanifibranor has demonstrated promising efficacy and safety data, positioning Inventiva as a potential leader in this space. Additionally, Inventiva's pipeline includes odiparcil, a dual PPARα/δ agonist in Phase 2 development for idiopathic pulmonary fibrosis (IPF), further expanding the company's reach in fibrotic diseases.

The NASH market, a major focus for Inventiva, is expected to witness substantial growth in the coming years, driven by the rising prevalence of obesity and diabetes. Several competitors are developing treatments for NASH, including Gilead Sciences, Intercept Pharmaceuticals, and Viking Therapeutics. Inventiva's lanifibranor has the potential to differentiate itself by targeting both inflammation and fibrosis associated with NASH. The company's ongoing Phase 3 trials are closely watched by investors, with positive results likely to propel Inventiva's growth.

Inventiva's competitive edge lies in its innovative approach to targeting fibrotic diseases. Lanifibranor's dual PPARα/γ agonism offers unique benefits, potentially addressing both metabolic and fibrotic aspects of liver disease. Odiparcil's dual PPARα/δ agonism holds promise for IPF, a disease with limited treatment options. Additionally, Inventiva's experienced management team and strong partnerships with leading pharmaceutical companies position the company for long-term success.

Inventiva SA: Advancing Medical Innovation in Inflammatory Diseases

Inventiva S.A. (IVA), a leading biopharmaceutical company headquartered in France, has garnered significant attention within the biotech sector for its promising pipeline of innovative treatments for inflammatory diseases. As the company navigates through 2023 and beyond, several factors suggest a favorable outlook for its future endeavors:

1. Potential Catalysts: IVA's robust clinical development pipeline boasts several potential catalysts that could significantly impact its future growth trajectory. Notably, the ongoing Phase IIb clinical trial evaluating lanifibranor, a novel PPAR agonist, in patients with non-alcoholic steatohepatitis (NASH) holds immense promise. Positive results from this trial could position IVA as a frontrunner in the rapidly expanding NASH therapeutics market. Additionally, the company's Phase II program investigating odiparcil in ulcerative colitis patients presents another potential catalyst for growth.

2. Strong Collaborations: Inventiva's strategic collaborations with reputable pharmaceutical companies play a pivotal role in accelerating its drug development efforts and expanding its global reach. The partnership with AbbVie for the development and commercialization of lanifibranor significantly bolsters IVA's resources and expertise, enabling it to efficiently navigate the complex regulatory and market access landscapes. Furthermore, the collaboration with Kyowa Kirin for odiparcil in Japan opens up new market opportunities for IVA's innovative treatments.

3. Robust Financial Position: IVA's sound financial position provides a firm foundation for executing its strategic plans. The company ended 2022 with a cash and cash equivalent balance of approximately €115 million. This financial strength enables IVA to continue investing in its clinical development programs, pursue promising research opportunities, and potentially expand its operations through partnerships or acquisitions.

4. Experienced Leadership Team: IVA benefits from a seasoned and accomplished leadership team with extensive experience in the biopharmaceutical industry. The team's expertise in drug development, regulatory affairs, and commercialization is instrumental in guiding the company through the complexities of clinical trials, regulatory approvals, and market launches. This leadership team's proven track record enhances IVA's ability to successfully navigate the challenges and seize opportunities that lie ahead.

Inventiva: Navigating Challenges and Prioritizing Efficiency

Inventiva S.A.'s ability to utilize resources and assets to maximize productivity and output has experienced several changes in recent years. Operating efficiency is a measure of how well a company converts inputs such as labor, materials, and capital into outputs like goods and services.

In 2021, Inventiva faced setbacks in its clinical trials for lanifibranor, a drug candidate for treating nonalcoholic steatohepatitis (NASH), resulting in a shift in focus towards advancing other assets in its pipeline. Despite these setbacks, the company took steps to streamline operations and reduce expenses, leading to improved efficiency in certain areas.

In 2022, Inventiva continued to optimize its operating structure, implementing measures to enhance efficiency further. The company sought to allocate resources judiciously, prioritizing the development of promising drug candidates and discontinuing projects with lower potential. This strategic approach has helped Inventiva to allocate its financial and human capital more effectively.

Looking ahead, Inventiva is expected to maintain its focus on operational efficiency. The company aims to maximize the value of its existing assets, optimize its research and development processes, and explore strategic collaborations to accelerate the development of new therapies. These efforts are likely to contribute to improved operating efficiency in the years to come, positioning Inventiva for sustainable growth and success.

Inventiva S.A: Navigating the Risks and Opportunities

Inventiva S.A. , a French biotech company focused on developing innovative treatments for fibrotic diseases and oncology, presents a unique investment opportunity. However, it is essential to assess the potential risks associated with this investment. Understanding these risks will help investors make informed decisions about whether to include Inventiva in their portfolio.

Scientific and Clinical Uncertainty:
Inventiva's success hinges on the successful development and commercialization of its drug candidates. Uncertainties surrounding the clinical trials and regulatory approval processes pose a significant risk. Setbacks or delays in these processes could adversely affect the company's progress and financial performance. Additionally, the highly competitive nature of the biopharmaceutical industry means that Inventiva faces stiff competition from established players.

Financial Dependence:
Inventiva is a relatively small company with limited financial resources. Its operations and clinical development programs rely heavily on external funding, primarily through partnerships and collaborations. Dependence on external funding sources exposes the company to potential funding interruptions or changes in partnership terms, which could hinder its ability to execute its plans. Moreover, the company's overall financial health and stability are subject to the success of its drug candidates and the timing of potential commercialization.

Market Acceptance and Reimbursement:
Even if Inventiva's drug candidates successfully navigate clinical trials and gain regulatory approval, market acceptance and reimbursement remain critical factors determining their commercial success. Acceptance by healthcare professionals and patients relies on the drug's efficacy, safety profile, and perceived value compared to existing treatments. Additionally, obtaining favorable reimbursement terms from healthcare payers is crucial for ensuring widespread patient access and sales growth.

Investment Considerations:
Investors considering Inventiva S.A. should carefully evaluate the company's risk profile in relation to their investment objectives and risk tolerance. The risks associated with scientific and clinical uncertainty, financial dependence, and market acceptance should be weighed against the potential rewards of successful drug development and commercialization. Thorough research, monitoring of clinical trial results, and understanding of the competitive landscape are essential for investors seeking potential upside in Inventiva's innovative treatments.


  1. Li L, Chen S, Kleban J, Gupta A. 2014. Counterfactual estimation and optimization of click metrics for search engines: a case study. In Proceedings of the 24th International Conference on the World Wide Web, pp. 929–34. New York: ACM
  2. Scholkopf B, Smola AJ. 2001. Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond. Cambridge, MA: MIT Press
  3. Batchelor, R. P. Dua (1993), "Survey vs ARCH measures of inflation uncertainty," Oxford Bulletin of Economics Statistics, 55, 341–353.
  4. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. MRNA: The Next Big Thing in mRNA Vaccines. AC Investment Research Journal, 220(44).
  5. P. Marbach. Simulated-Based Methods for Markov Decision Processes. PhD thesis, Massachusetts Institute of Technology, 1998
  6. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  7. E. van der Pol and F. A. Oliehoek. Coordinated deep reinforcement learners for traffic light control. NIPS Workshop on Learning, Inference and Control of Multi-Agent Systems, 2016.

Stop Guessing, Start Winning.
Get Today's AI-Driven Picks.

Click here to see what the AI recommends.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.